Highest-materiality recent filing
Nektar enters $150M ATM equity agreement; appoints Linda Rubinstein as interim CFO
Equity Distribution Agreement with Guggenheim Securities and H.C. Wainwright for up to $150M of common stock in at-the-market offerings.
Nektar Q1 net loss $44.9M; cash $731.6M; rezpegaldesleukin Phase 3 to start July
Net loss $44.9M ($1.82 loss per share) vs $50.9M in Q1 2025.
Nektar prices $325M upsized equity offering at $92/share; net proceeds ~$350.9M
Firm shares: 3,532,609 at $92.00; underwriters exercised option for 529,891 additional shares in full.
Nektar: REZOLVE-AA 52-wk SALT≤20 at 25.8% (low) and 27.6% (high) vs 6.7% placebo; p=0.049
SALT≤20 responders nearly doubled from week 36: low dose 25.8% (from 14.8%), high dose 27.6% (from 15.6%), placebo unchanged at 6.7%.
Nektar reports Q4 2025 net loss $36.1M ($1.78/sh); cash $245.8M plus $460M Feb 2026 offering
Revenue Q4 2025 $21.8M vs $29.2M YoY; full year $55.2M vs $98.4M.
Nektar Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants
Offering of 6,603,449 common shares at $58.00 and 293,103 pre-funded warrants at $57.9999; gross proceeds $400M.
Nektar REZOLVE-AD maintenance data show durable EASI-75/90, vIGA-AD responses
71% (monthly) and 83% (quarterly) maintained EASI-75 on 24 µg/kg; 85% and 63% maintained vIGA-AD 0/1.
Mean % SALT reduction at Week 36: 28.2% (24 µg/kg), 30.3% (18 µg/kg) vs 11.2% placebo (p=0.186, p=0.121).
Nektar reports REZOLVE-AD Phase 2b data showing asthma improvements with rezpegaldesleukin
Respegaldesleukin achieved statistically significant ACQ-5 reductions vs placebo in patients with AD and asthma (p<0.05).
Nektar Q3 net loss $35.5M ($1.87/sh), revenue $11.8M; cash $270.2M; rezpeg data at ACAAI
Net loss $35.5M ($1.87/sh) vs $37.1M ($2.66/sh) in Q3 2024.
Nektar Phase 2b rezpegaldesleukin meets primary endpoint; EASI-75 66% vs 34% placebo at week 16
All three rezpegaldesleukin dose arms met primary endpoint of mean % EASI improvement at week 16 (p<0.001 vs placebo).
Nektar Q2 net loss $41.6M; rezpegaldesleukin Fast Track; cash runway into Q1 2027
Revenue $11.2M Q2 2025 vs $23.5M Q2 2024; decrease due to sale of Huntsville facility.
Nektar Therapeutics prices $100M public offering at $23.50 per share
Nektar prices 4,255,320 shares at $23.50/share for gross proceeds of $100M.
REZOLVE-AD met primary endpoint: mean EASI improvement from baseline at week 16 for all three rezpegaldesleukin dose arms vs placebo (p<0.001).
Nektar boosts authorized shares to 390M, completes 1-for-15 reverse split effective June 8
Authorized common shares increased from 300M to 390M, effective June 6, 2025, stockholder-approved May 23, 2025.
Nektar Therapeutics announces 1-for-15 reverse stock split effective June 8
Board approved 1-for-15 reverse stock split effective June 8, 2025 at 11:59 p.m. ET.
Nektar Q1 net loss $50.9M, cash $220.7M; Phase 2 data expected June
Cash & marketable securities $220.7M, expected to fund operations into Q4 2026.
Nektar receives Nasdaq delisting notice for bid price below $1.00
Received Nasdaq notice on April 3, 2025 for non-compliance with minimum bid price rule.
Nektar enters ATM equity distribution agreement for up to $75M
ATM equity distribution agreement with Piper Sandler and BTIG allows sale of up to $75M of common stock.
Nektar Therapeutics reports Q4 net income $7.3M; rezpegaldesleukin Phase 2b data expected in 2025
Q4 net income $7.3M ($0.03 EPS) vs net loss $42.1M in Q4 2023; full year net loss $119M vs $276.1M.
Nektar CMO Mary Tagliaferri resigns; Brian Kotzin named interim CMO
Mary Tagliaferri resigned as SVP and CMO effective Feb 4, 2025, for personal reasons; no disagreement with company.
Nektar Q3 net loss narrows to $37.1M; sells Huntsville business for $90M
Net loss $37.1M ($0.18/sh) vs $45.8M ($0.24) in Q3 2023; revenue flat at $24.1M.
Nektar to sell Huntsville PEGylation plant to Ampersand for $90M
Total consideration $90M ($70M cash, $20M equity in new Ampersand portfolio co.).
Nektar Q2 net loss $52.4M, cash $290.6M, rezpegaldesleukin Phase 2b on track for H1 2025 topline
Net loss Q2 2024 $52.4M ($0.25/share) vs $51.1M ($0.27) Q2 2023; non-GAAP net loss $39.1M ($0.19).
Nektar Therapeutics regains Nasdaq minimum bid price compliance
Received Nasdaq notice on April 17, 2024, confirming compliance regained as of April 16, 2024.
Nektar Therapeutics raises $30M via pre-funded warrant to TCG Crossover Fund
Issued pre-funded warrant to purchase 25M shares of common stock at $1.20 per share, total $30M.
Nektar Q4 net loss $42.1M; cash $329.4M; $15M royalty amendment & $30M placement
Q4 revenue $23.9M (up from $22.0M); Q4 net loss $42.1M ($0.22/sh) vs $59.7M ($0.32).
Nektar repurchases 8.28M shares from BMS for $3M; reduces outstanding shares by 4.34%
Purchased 8,284,600 BMS-held restricted shares for $3,000,000 aggregate.
Nektar gets Nasdaq bid-price extension to May 2024; stock moves to Capital Market
Nasdaq granted additional 180-day period until May 20, 2024 to regain $1.00 minimum bid price.
Nektar reports Q3 net loss $45.8M, cash $372.7M; Phase 2b atopic derm study initiated
Net loss $45.8M ($0.24/shr) vs $59.0M y/y; non-GAAP loss $35.7M ($0.19/shr).
Nektar terminates collaboration agreement with Bristol-Myers Squibb for bempegaldesleukin
Parties entered letter agreement on Sept 6, 2023 to terminate the 2018 Strategic Collaboration Agreement.
Nektar Therapeutics Q2 net loss narrows to $51.1M; cash $409.4M, runway into mid-2026
Net loss $51.1M ($0.27/shr) vs $159.1M loss in Q2 2022; revenue $20.5M vs $21.6M.
Highest REZPEG dose (24 µg/kg) in atopic dermatitis achieved 83% mean EASI improvement (p=0.002 vs placebo).
Nektar receives Nasdaq notice for non-compliance with $1.00 minimum bid price rule
Notice dated May 26, 2023; stock closed below $1.00 for 30 consecutive business days.
Nektar Q1 2023 net loss $137M; regains rezpegaldesleukin rights from Lilly
Net loss of $137.0M ($0.73/share) vs. $90.4M ($0.49) in Q1 2022.
Nektar regains full rights to REZPEG from Lilly; plans Phase 2b in atopic dermatitis in 2023
Lilly terminated license agreement at will; termination effective July 22, 2023; Nektar gets all rights back.
Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.
On May 7, 2026, the Company announced that Sandra Gardiner will be retiring and stepping down as interim Chief Financial Officer of the Company, effective May 15, 2026.
On April 17, 2023, Nektar Therapeutics (the “Company”) announced that Jillian Thomsen will step down as the Chief Financial Officer of the Company effective as of April 17, 2023
Effective April 17, 2023, Sandra Gardiner, a partner in FLG Partners, LLC, a Silicon Valley chief financial officer services and board advisory firm (“FLG”), will be retained as the interim Chief Financial Officer and shall be the principal financial and accounting officer of the Company.
On April 17, 2023, Jillian Thomsen stepped down as the Chief Financial Officer of the Company and will depart the Company in June 2023 following a transition period.
On April 6, 2023, Karin Eastham informed the Board of Directors (the “Board”) of Nektar Therapeutics (the “Company”) that she has elected not to stand for re-election and will complete her term on the Board at the conclusion of the Company’s 2023 annual meeting of stockholders.
On July 1, 2022, Nektar Therapeutics (the “Company”) announced that Gil Labrucherie will step down as Chief Financial Officer and Chief Operating Officer of the Company, effective as of July 1, 2022.
On April 25, 2022 (the “Notice Date”), the Company announced that John Northcott will step down from the role of Senior Vice President and Chief Commercial Officer of the Company.
On July 1, 2022, the Company announced the promotion of Jillian Thomsen, who currently serves as Senior Vice President, Finance and Chief Accounting Officer, to the position of Senior Vice President and Chief Financial Officer, effective as of July 1, 2022.
John Northcott will step down as Senior Vice President and Chief Commercial Officer of the Company in June 2022.
On November 11, 2021, Diana M. Brainard, M.D. was appointed to the board of directors (the “ Board ”) of Nektar Therapeutics, a Delaware corporation (the “ Company ”), as a Class III Director
Max materiality 0.85 · Median 0.65 · Most common event other_material